Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.

@article{Fabbiani2009PharmacokineticVO,
  title={Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.},
  author={Massimiliano Fabbiani and Simona di Giambenedetto and Laura Bracciale and Alessandra Bacarelli and Enzo Ragazzoni and Roberto Cauda and Pierluigi Navarra and Andrea De Luca},
  journal={The Journal of antimicrobial chemotherapy},
  year={2009},
  volume={64 1},
  pages={109-17}
}
OBJECTIVES To assess the inter-individual and intra-individual plasma concentration variabilities of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) in routine clinical practice and to investigate their relationships with virological failure. METHODS We retrospectively enrolled HIV-infected patients undergoing therapeutic drug monitoring (TDM) of NNRTIs and PIs during routine outpatient visits. Plasma drug concentrations were measured by HPLC-UV and were… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

Efavirenz dissolution enhancement III: Colloid milling, pharmacokinetics and electronic tongue evaluation.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences • 2017
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Atazanavir (ATV) plasma concentrations at different times after drug uptake: associations with virologic response and hyperbilirubinemia (Abstract)

M Fabbiani, S Di Giambenedetto, E Ragazzoni
J Int AIDS Soc 2008; • 2008

BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy

B Gazzard
HIV Med • 2008

and Drug Administration

U. S. Foo
Guidance for Industry Bioanalytical Method Validation. www.fda.gov/cder/guidance/index.htm (1 December • 2008

Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2006

Similar Papers

Loading similar papers…